103.91
price up icon0.91%   0.94
after-market 시간 외 거래: 103.00 -0.91 -0.88%
loading
전일 마감가:
$102.97
열려 있는:
$102.97
하루 거래량:
399.41K
Relative Volume:
0.58
시가총액:
$5.41B
수익:
$338.46M
순이익/손실:
$-310.96M
주가수익비율:
-15.91
EPS:
-6.53
순현금흐름:
$-132.82M
1주 성능:
+0.20%
1개월 성능:
-3.48%
6개월 성능:
+19.00%
1년 성능:
+31.65%
1일 변동 폭
Value
$102.26
$104.83
1주일 범위
Value
$102.00
$106.60
52주 변동 폭
Value
$72.21
$139.13

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name
명칭
Axsome Therapeutics Inc
Name
전화
(212) 332-3241
Name
주소
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Name
직원
589
Name
트위터
Name
다음 수익 날짜
2025-02-18
Name
최신 SEC 제출 서류
Name
AXSM's Discussions on Twitter

AXSM을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
AXSM
Axsome Therapeutics Inc
103.91 5.41B 338.46M -310.96M -132.82M -6.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-03 개시 Oppenheimer Outperform
2025-04-07 개시 Jefferies Buy
2025-02-11 개시 Deutsche Bank Buy
2024-12-31 재확인 Mizuho Outperform
2024-09-03 개시 Wells Fargo Overweight
2024-08-06 업그레이드 BofA Securities Neutral → Buy
2024-07-22 개시 Needham Buy
2024-04-29 업그레이드 Morgan Stanley Equal-Weight → Overweight
2024-03-19 개시 Robert W. Baird Outperform
2024-02-06 개시 UBS Buy
2024-01-25 개시 RBC Capital Mkts Outperform
2023-12-13 개시 Citigroup Buy
2023-08-08 업그레이드 BofA Securities Underperform → Neutral
2023-01-05 개시 Piper Sandler Neutral
2022-11-01 개시 Loop Capital Buy
2022-09-07 재개 Mizuho Buy
2021-08-10 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-06-10 개시 Berenberg Buy
2021-01-08 개시 Jefferies Buy
2020-12-16 개시 Mizuho Buy
2020-09-29 개시 BofA Securities Underperform
2020-09-10 개시 Morgan Stanley Overweight
2020-04-28 재확인 H.C. Wainwright Buy
2020-04-14 개시 Cowen Outperform
2019-12-30 재확인 H.C. Wainwright Buy
2019-12-17 재확인 H.C. Wainwright Buy
2019-12-16 재확인 Guggenheim Buy
2019-10-16 개시 Guggenheim Buy
2019-09-18 개시 William Blair Outperform
2019-05-28 개시 SunTrust Buy
2019-05-23 재확인 H.C. Wainwright Buy
2019-04-08 개시 SVB Leerink Outperform
2019-03-15 재확인 H.C. Wainwright Buy
2016-10-03 재개 Brean Capital Buy
2015-12-15 개시 Cantor Fitzgerald Buy
2015-12-14 개시 Ladenburg Thalmann Buy
모두보기

Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스

pulisher
Jun 18, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) General Counsel Hunter R. Murdock Sells 7,500 Shares - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Axsome therapeutics’ general counsel sells $2.28 million in stock - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM): When Will It Breakeven? - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Axsome Therapeutics to Present SYMBRAVO® Clinical Data at the 67th Annual Scientific Meeting of the American Headache Society - Nasdaq

Jun 18, 2025
pulisher
Jun 18, 2025

Prosperity Wealth Management Inc. Buys New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

SYMBRAVO Breakthrough: New Data Reveals Effectiveness in CGRP-Resistant Migraine Patients - Stock Titan

Jun 18, 2025
pulisher
Jun 16, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $172.33 Average Target Price from Analysts - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Axsome Therapeutics (AXSM) Supports Migraine Awareness and Commu - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

Axsome Therapeutics Partners With Migraine Association to Help 40 Million US Patients Find Better Days - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

GAMMA Investing LLC Purchases 21,986 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jun 16, 2025
pulisher
Jun 15, 2025

Q3 EPS Forecast for Axsome Therapeutics Decreased by Analyst - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Royal Bank of Canada Has Lowered Expectations for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Axsome initiated with an Outperform at Oppenheimer on revenue boost - MSN

Jun 15, 2025
pulisher
Jun 15, 2025

Rhumbline Advisers Increases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jun 15, 2025
pulisher
Jun 14, 2025

Axsome fell after FDA refuses to review AXS-14 application - MSN

Jun 14, 2025
pulisher
Jun 14, 2025

Axsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from HC Wainwright - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Equities Analysts Issue Forecasts for AXSM FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market By Investing.com - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 14, 2025

Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

Assenagon Asset Management S.A. Purchases 623,717 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Mark L. Jacobson Sells 25,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

RBC Capital Adjusts Price Target for AXSM, Maintains Outperform - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by Pallas Capital Advisors LLC - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Needham & Company LLC Cuts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $150.00 - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Axsome Therapeutics (AXSM) Target Price Adjusted by RBC Capital - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Axsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

RBC Capital Adjusts Price Target for AXSM, Maintains Outperform Rating | AXSM Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Axsome Therapeutics (AXSM) Target Price Adjusted by RBC Capital | AXSM Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

RBC Lowers Price Target on Axsome Therapeutics to $186 From $193, Keeps Outperform Rating - MarketScreener

Jun 12, 2025
pulisher
Jun 11, 2025

Axsome Presents Positive Phase 3 Data for AXS-12 in Narcolepsy at SLEEP 2025 - HCPLive

Jun 11, 2025
pulisher
Jun 11, 2025

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OSCR, AXSM and ET - ACCESS Newswire

Jun 11, 2025
pulisher
Jun 11, 2025

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

Axsome Therapeutics Highlights Seven Presentations on AXS-12 and Solriamfetol at SLEEP 2025 Conference - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

Axsome Unveils Phase 3 Narcolepsy Trial Results Among 7 Major Presentations at SLEEP 2025 - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : Axsome Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02 - MarketScreener

Jun 11, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics, Inc. Announces Availability of Symbravo (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine with or Without Aura in Adults - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit - simplywall.st

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics Launches SYMBRAVO for Migraine Relief - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Deutsche Bank Adjusts Axsome Therapeutics Price Target to $185 From $190, Maintains Buy Rating - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics (AXSM) Launches SYMBRAVO for Migraine Relief in the U.S. | AXSM Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Revolutionary Migraine Drug SYMBRAVO Now Available: Fast-Acting Relief Targets Multiple Pain Pathways - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics (NASDAQ:AXSM) Given New $150.00 Price Target at Needham & Company LLC - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Canada

Jun 10, 2025
pulisher
Jun 09, 2025

Axsome’s fibromyalgia drug application hits FDA roadblock By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Axsome Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:AXSM - Benzinga

Jun 09, 2025

Axsome Therapeutics Inc (AXSM) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Axsome Therapeutics Inc 주식 (AXSM) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Murdock Hunter R.
General Counsel
Jun 23 '25
Option Exercise
29.91
6,014
179,879
6,014
Murdock Hunter R.
General Counsel
Jun 20 '25
Sale
102.47
7,500
768,525
0
Murdock Hunter R.
General Counsel
Jun 23 '25
Sale
100.12
6,014
602,122
0
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):